Premium
Topiramate therapy for paroxysmal kinesigenic choreoathetosis
Author(s) -
Huang YuanGui,
Chen YunChun,
Du Fang,
Li Rui,
Xu GeLin,
Jiang Wen,
Huang Jing
Publication year - 2005
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20283
Subject(s) - topiramate , choreoathetosis , medicine , dose , anticonvulsant , anesthesia , pediatrics , epilepsy , pharmacology , dystonia , psychiatry
We observed the clinical efficacy of topiramate for paroxysmal kinesigenic choreoathetosis (PKC). Topiramate was administered as a monotherapy with titrated dosages to 8 patients with PKC. Target daily dose of topiramate was 100 to 200 mg; the follow‐up period ranged from 8 months to 2 years. All of the patients became attack‐free, and side effects were mild. The results show that topiramate is effective as a monotherapy for treating patients with PKC. The response to topiramate indicates that the disease may be caused by an ion channel defect. © 2004 Movement Disorder Society